Covalent inhibition of the SARS-CoV-2 NiRAN domain via an active-site cysteine
Journal of Biological Chemistry · 2025
DOI: 10.1016/j.jbc.2025.108378 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2025. Verfasst von Genaro Hernandez und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, Texas, USA. Hauptthemen laut MEDLINE: SARS-CoV-2, Antiviral Agents, Cysteine, Viral Nonstructural Proteins. Die Arbeit nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIGMS NIH HHS, NIH HHS.
Abstract (Originalsprache)
The kinase-like nidovirus RdRp-associated nucleotidyl transferase (NiRAN) domain of nsp12 in SARS-CoV-2 catalyzes the formation of the 5' RNA cap structure. This activity is required for viral replication, offering a new target for the development of antivirals. Here, we develop a high-throughput assay to screen for small molecule inhibitors targeting the SARS-CoV-2 NiRAN domain. We identified NiRAN covalent inhibitor 2 (NCI-2), a compound with a reactive chloromethyl group that covalently binds to an active site cysteine (Cys53) in the NiRAN domain, inhibiting its activity. NCI-2 can enter cells, bind to, and inactivate ectopically expressed nsp12. A cryo-EM reconstruction of the SARS-CoV-2 replication-transcription complex bound to NCI-2 offers a detailed structural blueprint for rational drug design. Although NCI-2 showed limited potency against SARS-CoV-2 replication in cells, our work lays the groundwork for developing more potent and selective inhibitors targeting the NiRAN domain. This approach presents a promising therapeutic strategy for effectively combating COVID-19 and potentially mitigating future coronavirus outbreaks.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
- Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, Texas, USA; Howard Hughes Medical Institute, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
- Department of Microbiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
- Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
- Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, Texas, USA; Howard Hughes Medical Institute, University of Texas Southwestern Medical Center, Dallas, Texas, USA; Harold C. Simmo…
Förderung
- NIAID NIH HHS
- NIGMS NIH HHS
- NIH HHS
- Cancer Prevention and Research Institute of Texas
- Howard Hughes Medical Institute
- Welch Foundation
- National Institutes of Health
Zitieren
APA
Hernandez, G., Osinski, A., Majumdar, A., Eitson, J. L., Antczak, M., Pawłowski, K., Niederstrasser, H., Servage, K. A., Posner, B., Schoggins, J. W., Ready, J. M., & Tagliabracci, V. S. (2025). Covalent inhibition of the SARS-CoV-2 NiRAN domain via an active-site cysteine. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2025.108378
Vancouver
Hernandez G, Osinski A, Majumdar A, Eitson JL, Antczak M, Pawłowski K, et al. Covalent inhibition of the SARS-CoV-2 NiRAN domain via an active-site cysteine. Journal of Biological Chemistry. 2025. doi:10.1016/j.jbc.2025.108378
BibTeX
@article{Hernandez2025,
author = {Hernandez, Genaro and Osinski, Adam and Majumdar, Abir and Eitson, Jennifer L and Antczak, Monika and Pawłowski, Krzysztof and Niederstrasser, Hanspeter and Servage, Kelly A and Posner, Bruce and Schoggins, John W and Ready, Joseph M and Tagliabracci, Vincent S},
title = {Covalent inhibition of the SARS-CoV-2 NiRAN domain via an active-site cysteine},
journal = {Journal of Biological Chemistry},
year = {2025},
doi = {10.1016/j.jbc.2025.108378}
}
EUVIMED